Chunk #21 — Current Status of Drug Labeling and Pharmacogenomic Testing Guidelines — Labeling for Selective Serotonin Reuptake Inhibitors

Source

Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options.

Embedded

yes

Text

The differences in pharmacokinetic parameters between metabolizer groups have been recognized for citalopram and fluvoxamine. The FDA label for citalopram recommends a maximum dose of 20 mg/day in known PMs.23 Regarding fluvoxamine, the FDA labeling recommends caution when the drug is administered to PMs or when it is coadministered with CYP2D6 inhibitors.23 Labeling for fluoxetine and paroxetine include only general information in the drug-drug interaction section, in view of the fact that both agents have the ability to inhibit CYP2D6.23